Current Users Register on Our Website to Access Benefits and Open Communication Pathways New Users, Activate Your Warranty! Check out our updated website.  We improved access to valuable information, and streamlined content.  There are some new functionalities scheduled to go live within the next few weeks. If you are a current Myoguide owner, please Register  your…

Myoguide DOC: Saves Time, Increases Productivity, and Improves Communication TORONTO, April 11, 2017 – Intronix Technologies will be launching “Myoguide DOC”, a comprehensive software package designed to help clinicians who inject Botulinum Toxins, such as Botox®, Dysport® and Xeomin® to manage their patient’s spasticity and pain. Myoguide DOC is the first integrated graphics driven patient…

TORONTO, December 15, 2014 – Intronix Technologies will be collaborating with Western University’s Department of Electrical and Computer Engineering to develop technology to be incorporated into rehabilitation devices. Canadian-based innovator, Intronix Technologies, will be working with Dr. Ana Luisa Trejos, Assistant Professor in the Department of Electrical and Computer Engineering at Western University, and Associate…

Intronix Technologies’ innovative Myoguide EMG guided injection system will be available to play with at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly, November 13–16, 2014 at the San Diego Convention Center. Myoguide is now available throughout Ambu’s worldwide distribution network. You can find Intronix at booth #306 and Ambu USA at…

TORONTO, Oct. 27, 2014 /PRNewswire/ — Ambu, a leading global supplier of medical devices, has signed a distribution agreement with Intronix Technologies. Intronix Technologies’ innovative Myoguide EMG guided injection system will be available through Ambu’s worldwide network of distributors, which already services Ambu’s customers locally. The revolutionary Myoguide™ Needle EMG Guided Injection System has breakthrough…

Intronix will be on hand at the upcoming assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) to discuss the company’s most recent advance in guided injection technology.

Myoguide distribution has just started in the USA. We are pleased to welcome Myoguide Inc. as our US division dedicated to the US market.

Myoguide receives a US FDA 510(k) K111985. We are preparing to complete the process for FDA clearance and will be launching an E-Commerce section from our website. The E-Commerce system will serve US and Canadian clinicians wishing to order Myoguide directly.